723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover
Status:
Completed
Trial end date:
2009-08-14
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, placebo-controlled 4-period cross-over study to assess
the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg)
and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal
allergic rhinitis.